A comparison of f-fdg gamma camera pet, mammography and ultrasonography in demonstrating primary disease in locally advanced breast cancer

Nuclear Medicine Communications

Volumn 25, Issue 7, 2004, Pages 721-725

  Marshall, Christopher ^a   Mustafa, Sayed ^a   Wheatley, David C ^a   Eremin, Jennifer E ^a   El Sheemy, Mohammed ^a   Jibril, Jibril A ^a   Eremin, Oleg ^a   Griffiths, Peter A ^a  

^a LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Gamma camera; Positron emission tomography

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOMAMMOGRAPHY; EQUIPMENT; FEASIBILITY STUDY; FEMALE; HUMAN; INSTRUMENTATION; MAMMOGRAPHY; METHODOLOGY; MIDDLE AGED; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SCINTILLATION CAMERA; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL EXAMINATION; CYCLOTRON; DISEASE COURSE; ECHOGRAPHY; GENERAL HOSPITAL; HISTOPATHOLOGY; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; NUCLEAR MEDICINE; PATIENT SELECTION; POSTOPERATIVE PERIOD; RADIOSENSITIVITY; STATISTICAL SIGNIFICANCE; SYSTEM ANALYSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EQUIPMENT FAILURE ANALYSIS; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA CAMERAS; HUMANS; MAMMOGRAPHY; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, MAMMARY;

EID: 3142548887     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000130239.76326.ca     Document Type: Article

References (24)

1. Quinn MJ, Babb P, Brook A, Kirby L, Jones J. Cancer Trends in England and Wales 1950-1999. Studies on Medical and Population Subjects no 66. London: The Stationery Office Ltd; 2001.
2. NHS Breast Screening Programme/British Association of Surgical Oncology Breast Group. An Audit of Screen Detected Cancers for the Year of Screening April 1999 to March 2000. NHS Breast Screening Programme April 2001.
3. Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS Breast Screening programme on Mortality from Breast Cancer in England and Wales 1990-8: comparison of observed with predicted mortality. Br Med J 2000; 321:665-669.
4. Miller WR, Ellis IO, Sainsbury JR, Dixon JM. ABC of breast disease. Prognostic factors. Br Med J 1994; 309:1573-1576.
5. Schottenfeld D, Nash AG, Robbins GF, Beatty EJ. Ten year results of the treatment of operable breast carcinoma. Cancer 1976; 38:1001-1007.
6. Steele RJC. The axillary lymph nodes in breast cancer. Seven years on. J R Coll Surg Edin 1983; 28:282-291.
7. Wahl RL. Overview of the current status of PET in breast cancer imaging. Q J Nucl Med 1998; 42:1-7.
8. 18F-FDG. Detection with a dual-head coincidence camera: a review. Eur J Nucl Med 2001; 28:763-778.
9. Delbeke D, Patton JA, Martin WH, Sandier MP. FDG PET and dual head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders. J Nucl Med 1999; 40:110-117.
10. Tatsumi M, Yutani K, Watanabe Y, Miyoshi S, Tomiyama N, Johkoh T, et al. Feasibility of fluorodeoxyglucose dual head gamma camera coincidence imaging in the evaluation of lung cancer: Comparison with FDG PET. J Nucl Med 1999; 40:566-573.
11. 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. J Nucl Med 1999; 40:574-578.
12. Spiessl B, Beahrs OH, Hermanek P. TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. New York: Springer-Verlag; 1989, pp. 173-183.
13. Fornage BD, Toubas O, Morel M. Clinical, mammographic and sonographic determination of preoperative breast cancer size. Cancer 1987; 60:765-771.
14. Yutani K, Tatsumi M, Shiba E, Kusuoka H, Nishimura T. Comparison of dual head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node status. J Nucl Med 1999; 40:1003-1008.
15. Bendriem B, Townsend DW. The Theory and Practice of 3D PET. London: Kluwer Academic Publishers; 1988, pp. 1-7.
16. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport D. Exact and approximate rebinning algorithms for 3D PET data. IEEE Trans Med Imag 1997; 16:145-158.
17. Liow J-S, Strother SC, Rehm K, Rottenburg A. Improved resolution for PET. Volume imaging through three-dimensional iterative reconstruction. J Nucl Med 1997; 38:1623-1630.
18. Kinahan PE, Michel C, Defrise M, Townsend DW, Sibomana M, Lonneux M, et al. Fast iterative image reconstruction of 3D PET data. In: Proceedings of the IEEE Nuclear Science Symposium and Medical Imaging Conference, 5-8 November 1996, Anaheim, California. pp. 1918-1922.
19. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187:743-750.
20. 18FDG for detection and nodal staging of non-small cell lung cancer: accuracy as determined by 2 independent observers. J Nucl Med 2003; 44:336-340.
21. Chan WL, Freund J, Pocock NAS, Szeto E, Chan F, Sorenson BJ, et al. Coincidence detection FDG PET in the management of oncological patients: attenuation correction versus non-attenuation correction. Nucl Med Commun 2001; 22:1185-1192.
22. Bird RE, Wallace DW, Yankaskas BC. Analysis of cancers missed at screening mammography. Radiology 1992; 184:613-617.
23. 99mTc-MDP bone scintigraphy. Nucl Med Commun 2001; 22:875-879.
24. Nakamot Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med 2003; 28:302-307.